one
daunt
challeng
face
modern
medicin
lie
understand
treatment
tumor
heterogen
tumor
show
intratumor
heterogen
genom
proteom
level
mark
impact
respons
therapeut
target
therapeut
targetrel
gene
express
pathway
affect
hypoxia
cellular
stress
howev
find
target
eukaryot
initi
factor
eif
phosphoryl
form
gener
homogen
express
throughout
tumor
regardless
presenc
hypoxia
cellular
stress
condit
open
excit
possibl
malign
could
treat
therapi
combin
target
phosphoryl
immun
checkpoint
inhibitor
chemotherapi
owe
increas
incid
cancer
second
common
caus
death
develop
countri
lead
caus
death
individu
year
age
number
cancerrel
death
expect
grow
due
increas
life
expect
lifestyl
risk
factor
although
current
treatment
improv
patient
surviv
result
remain
dismal
advanc
diseas
exampl
surviv
rate
stage
iv
lung
cancer
breast
cancer
patient
metastat
diseas
contrast
surviv
patient
situ
breast
cancer
exce
inde
despit
develop
new
arsen
molecular
target
therapi
last
decad
patient
surviv
advanc
cancer
improv
one
main
reason
disappoint
outcom
pervas
heterogen
express
drug
target
within
human
tumor
cancer
view
group
heterogen
diseas
aris
small
number
initi
event
phenotyp
diverg
progress
due
environment
context
site
origin
acquisit
differ
mutat
requir
surviv
individu
patient
respons
tumor
heterogen
observ
genet
proteom
morpholog
environment
level
tumor
cell
adapt
often
lead
use
redund
signal
pathway
respons
stress
hypoxia
reduc
nutrient
avail
within
tumor
bed
variat
strength
stressor
event
correspond
respons
result
signific
degre
heterogen
gene
express
cell
need
respond
acut
other
review
underscor
natur
eukaryot
initi
factor
eif
malign
tumor
critic
effector
cell
signal
network
summar
find
phosphoryl
form
term
show
predominantli
homogen
express
pattern
within
tumor
bed
featur
predict
action
hold
signific
consequ
cancer
therapi
fig
diagram
repres
clonal
select
accord
darwinian
model
bestadapt
clone
due
genet
epigenet
advantag
better
interplay
neighbor
cell
surviv
prolifer
becom
domin
clone
new
select
barrier
appear
tumor
clonal
composit
vari
time
although
microscop
chang
subtl
evid
b
clonal
cooper
featur
complement
puzzl
diagram
illustr
contribut
individu
cell
clone
differ
tumorpromot
featur
format
tumor
main
featur
clonal
popul
within
tumor
shown
legend
left
side
cooper
differ
clone
result
differ
function
consequ
tumor
summar
middl
figur
clonal
evolut
cancer
progress
complex
molecular
scenario
respons
tumor
initi
tumor
progress
well
establish
singl
tumor
cell
clone
novel
genet
alter
aris
constantli
select
accord
darwinian
model
concomitantli
also
cross
talk
tumor
clone
microenviron
affect
abil
tumor
surviv
prolifer
fact
cooper
clone
microenviron
similar
tumor
consortium
fig
new
genet
alter
driven
genet
instabl
one
hallmark
tumor
cell
small
proport
total
mutat
burden
relat
process
clonal
evolut
passeng
mutat
biolog
relev
addit
treatment
alter
clonal
heterogen
select
resist
cell
perturb
microenvironment
condit
epigenet
differ
clone
critic
tumor
heterogen
mani
associ
aberr
dna
methyl
pattern
histon
modif
microrna
transcriptom
relat
microenviron
factor
thu
genom
epigenom
divers
enabl
malign
tumor
clone
acquir
capabl
surviv
prolifer
invad
neighbor
distant
tissu
microenviron
appear
import
select
bestadapt
clone
contributor
includ
neighbor
cell
eg
fibroblast
immun
cell
growth
factor
cytokin
hypoxia
nutrient
avail
henc
variat
among
tumor
microenviron
may
respons
phenotyp
heterogen
observ
within
tumor
bed
consequ
microenviron
may
also
impact
select
specif
clone
differ
drivermainten
mutat
topolog
segreg
area
tumor
togeth
affect
evolutionari
trajectori
diseas
fig
proteom
complex
tumor
must
fulli
understood
develop
effect
therapeut
strategi
pathologist
long
recogn
cell
within
given
tumor
express
amount
larg
number
protein
exampl
express
cyclin
mantl
cell
lymphoma
homogen
even
tumor
cell
carri
signatur
transloc
likewis
hormon
receptor
express
breast
carcinoma
often
nonhomogen
irregular
within
given
tumor
bed
protein
intratumor
heterogen
mirror
case
transcript
level
well
document
singlecel
rnasequenc
glioblastoma
moreov
latter
studi
note
variat
express
level
differ
cell
signal
receptor
cell
prolifer
marker
addit
differ
posttransl
modif
given
protein
among
cancer
cell
singl
tumor
document
consequ
pervas
lack
uniform
cancer
cell
grim
patient
major
caus
treatment
failur
mani
patient
particularli
treat
molecular
target
therapi
fraction
cancer
cell
tumor
express
particular
drug
target
evolv
longer
depend
presenceact
stand
reason
cell
fail
elimin
target
therapi
case
point
human
epiderm
growth
factor
receptor
breast
cancer
classif
requir
cell
stain
posit
immunocytochemistri
clearli
treatment
therapi
expect
cur
context
similarli
therapi
base
rapamycin
fail
uneven
heterogen
express
pmtor
noteworthi
target
express
issu
may
also
affect
outcom
immunotherapeut
approach
patient
b
cell
malign
treat
chimer
antigen
receptor
car
cell
target
initi
respond
therapi
relaps
relaps
appear
tumor
cell
express
novel
isoform
aris
altern
splice
lack
exon
encod
antigen
epitop
one
way
around
problem
combin
multipl
therapi
tumor
mutat
profil
appropri
clinic
trial
requir
ensur
result
combin
antagonist
choos
target
whose
express
level
vari
significantli
among
cancer
cell
whose
express
extinguish
ie
essenti
target
logic
step
deal
issu
heterogen
potenti
target
includ
compon
translat
apparatu
essenti
biochem
process
recent
experi
show
optim
therapeut
index
obtain
process
target
cancer
cell
two
import
regulatori
signal
transduct
pathway
modul
cellular
translat
rate
pathway
pathway
crucial
develop
target
therapi
mani
compon
chang
vast
major
human
cancer
eg
ra
raf
gener
underappreci
compon
translat
regulatori
machineri
name
involv
ribosom
recruit
phase
translat
initi
fall
control
pathway
fig
complex
consist
capbind
protein
deadbox
rna
helicas
larg
scaffold
protein
regul
ribosom
recruit
mrna
templat
step
translat
initi
thought
ratelimit
protein
synthesi
assembl
regul
mtor
via
phosphoryl
three
best
studi
well
bind
prevent
complex
format
mtor
activ
occur
broad
rang
human
cancer
caus
direct
phosphoryl
dissoci
consequ
stimul
format
discrimin
differ
mrna
therefor
increas
level
activ
caus
select
chang
translatom
although
featur
respons
mrna
discrimin
complet
understood
cap
access
leader
secondari
structur
import
contributor
form
inhibitori
complex
phosphoryl
former
lead
degrad
allow
enter
complex
addit
directli
phosphoryl
upon
activ
pathway
also
associ
select
increas
translat
mechanist
basi
remain
elucid
harbor
seven
phosphoryl
site
although
mtor
promin
kinas
target
site
kinas
atm
also
phosphoryl
therefor
phosphoryl
consequ
mani
differ
oncogen
event
modul
dispar
signal
pathway
occur
via
sever
mechan
includ
amplif
mutat
growth
factor
receptor
mutat
critic
oncogen
eg
pten
atm
ra
current
understand
perturb
translat
initi
cancer
cell
ratio
critic
sustain
oncogen
featur
transform
cell
ultim
essenti
node
may
act
bottleneck
funnel
factor
sustain
transform
regardless
upstream
oncogen
alter
fig
past
decad
analyz
human
tumor
sampl
assess
express
membran
receptor
egfr
compon
rasraferk
pathway
effector
p
fig
ah
invas
ductal
carcinoma
ag
h
immunohistochemistri
b
c
e
pakt
f
pmtor
g
h
immunohistochemistri
perform
describ
previous
use
follow
primari
antibodi
abcam
cell
signal
cell
signal
cell
signal
pmtor
cell
signal
pakt
cell
signal
abcam
found
increas
amount
total
well
associ
malign
progress
advers
prognosi
sever
tumor
includ
breast
lung
ovari
endometrium
glioma
prostat
cancer
regardless
upstream
oncogen
alter
fig
group
confirm
prognost
import
factor
addit
tumor
type
tabl
includ
colon
cancer
nasopharyng
carcinoma
hepatocellular
carcinoma
astrocytoma
lung
cancer
melanoma
importantli
central
regul
metastat
progress
fig
thu
node
appear
act
restrict
point
essenti
oncogen
featur
selfsuffici
growth
signal
serv
highli
relev
molecular
marker
malign
potenti
interestingli
express
phosphoryl
form
appar
even
presenc
upstream
receptor
kinas
overexpress
eg
akt
mtor
erk
suggest
mechan
involv
regul
express
pakt
pmtor
highli
heterogen
within
tumor
wherea
express
homogen
fig
may
due
activ
statu
global
growth
signal
prolif
network
abl
maintain
certain
flux
threshold
rather
necess
maintain
activ
specif
player
even
tumor
show
constitut
express
egfr
global
gene
express
program
necessarili
perman
fix
homogen
cell
interestingli
geograph
context
tumor
cell
may
imping
express
level
pathway
exampl
marker
highli
express
invas
front
around
necrot
area
suggest
ischemia
microenvironment
factor
imping
express
activ
fig
microenviron
key
role
select
bestadapt
cancer
clone
alter
commun
network
differ
cancer
cell
type
aberr
inform
flow
cancer
cell
lead
alter
gene
regulatori
network
support
cancer
hallmark
influenc
featur
cytokin
exosom
hypoxia
starvat
oxid
stress
fig
fig
ad
lowgrad
lung
adenocarcinoma
eh
highgrad
lung
squamou
carcinoma
immunohistochemistri
e
b
f
c
g
h
immunohistochemistri
perform
describ
previous
respect
modul
translat
program
thought
ensur
express
factor
confer
resist
cellular
stress
fig
malign
cell
capdepend
pathway
highli
upregul
interfer
translat
program
shown
attract
venu
novel
therapeut
ultim
prevent
adapt
tumor
cell
stress
condit
main
therapeut
approach
target
capdepend
translat
machineri
summar
ref
direct
express
interact
bind
complex
structur
helicas
activ
phosphoryl
statu
kinas
activ
among
differ
strategi
prevent
capdepend
translat
stress
condit
believ
inhibit
mnk
may
power
way
increas
efficaci
antitumor
agent
phosphoryl
downstream
target
shown
confer
resist
cellular
stress
genom
damag
lack
nutrient
oxid
stress
fig
fact
sever
compani
develop
inhibitor
activ
least
one
alreadi
studi
clinic
phase
ii
trial
impress
data
independ
prognost
factor
associ
poor
respons
endocrin
therapi
karlsson
et
al
predict
surviv
anthracyclin
chemotherapi
breast
cancer
patient
heikkinen
et
al
express
relat
breast
cancer
surviv
modul
coleman
et
al
correl
grade
prognosi
breast
cancer
rojo
et
al
high
independ
predictor
recurr
breast
cancer
li
et
al
cervix
overexpress
predict
recurr
reduc
surviv
cervic
carcinoma
benavent
et
al
cn
independ
prognost
factor
astrocytoma
et
al
express
increas
tumor
grade
predict
surviv
astrocytoma
korkolopoul
et
al
colon
high
express
associ
poor
prognosi
chen
et
al
high
express
associ
advanc
stage
poor
prognosi
chao
et
al
endometrium
associ
highgrad
endometri
carcinoma
wors
prognosi
castellvi
et
al
associ
stage
highgrad
tumor
darbesfahani
et
al
esophagu
express
chemoradiotherapi
predictor
recurr
wors
surviv
esophag
carcinoma
chao
et
al
associ
poor
prognosi
earli
stage
esophag
carcinoma
yeh
et
al
head
neck
express
associ
tumor
stage
lymph
node
metastasi
grade
differenti
han
et
al
independ
prognost
factor
nasopharyng
carcinoma
zheng
et
al
kidney
associ
poor
prognosi
transloc
renal
cell
carcinoma
qu
et
al
independ
prognost
factor
clear
cell
renal
cell
carcinoma
campbel
et
al
prognost
predictor
patient
metastat
renal
cell
carcinoma
nishikawa
et
al
liver
overexpress
independ
indic
overal
surviv
hepatocarcinoma
jiang
et
al
overexpress
cholangiocarcinoma
poor
differenti
lymph
node
metastasi
independ
prognost
factor
fang
et
al
lung
express
associ
poor
prognosi
smallcel
lung
cancer
roh
et
al
predict
poor
prognosi
nonsmallcel
lung
cancer
lee
et
al
prognost
factor
stage
lung
adenocarcinoma
seki
et
al
high
express
correl
poor
prognosi
lung
adenocarcinoma
wang
et
al
melanoma
associ
melanoma
thick
overal
surviv
khosravi
et
al
associ
poor
surviv
melanoma
oreilli
et
al
ovari
prognost
factor
ovarian
cancer
castellvi
et
al
stomach
overexpress
tumor
lymph
node
metastasi
tapia
et
al
prognost
factor
gastric
cancer
patient
correl
advanc
stage
jiao
et
al
obtain
preclin
model
diffus
larg
b
cell
lymphoma
nonsmallcel
lung
carcinoma
breast
adenocarcinoma
moreov
inhibitor
enhanc
effici
checkpoint
blockad
inhibitor
similarli
blockag
phosphoryl
inhibit
upstream
signal
activ
eg
mtor
decreas
level
dampen
capdepend
translat
tumor
cell
growth
summari
tumor
heterogen
must
first
foremost
consid
treat
oncologist
cancer
diagnosi
key
factor
determin
therapeut
target
follow
mutat
profil
know
intratumor
heterogen
dynam
occur
multipl
level
follow
darwinian
model
still
unresolv
number
biopsi
section
requir
primari
specimen
determin
extent
molecular
target
heterogen
moreov
relaps
metastas
need
analyz
understand
differ
primari
tumor
given
complex
issu
collabor
among
oncologist
radiologist
pathologist
bioinformatician
molecular
biologist
requir
offer
best
care
patient
final
clearli
paramount
import
explor
intervent
strategi
target
critic
factor
involv
regul
translat
rigor
evalu
combin
smallmolecul
inhibitor
therapeut
eg
cytotox
target
therapi
immunotherapi
issu
proteom
heterogen
start
therapeut
address
fund
sryc
acknowledg
support
fondo
de
investigacion
sanitaria
pi
rede
de
cooperativa
en
salud
rticc
rd
generalitat
de
catalunya
agaur
ciberonc
conflict
interest
author
declar
conflict
interest
open
access
articl
licens
creativ
common
attributionnoncommercialnoderiv
intern
licens
permit
noncommerci
use
share
distribut
reproduct
medium
format
long
give
appropri
credit
origin
author
sourc
provid
link
creativ
common
licens
permiss
licens
share
adapt
materi
deriv
articl
part
imag
third
parti
materi
articl
includ
articl
creativ
common
licens
unless
indic
otherwis
credit
line
materi
materi
includ
articl
creativ
common
licens
intend
use
permit
statutori
regul
exce
permit
use
need
obtain
permiss
directli
copyright
holder
view
copi
licens
visit
http
